1 (888) 354-8168
info@fulgentoncology.com
Call Us Email Us
Client Portal Log In
Log In
Our Products & Services
Resources
For Cancer Care Teams
For Patients
About Us
Our Products & Services
Resources
For Cancer Care Teams
For Patients
About Us
Welcome CSI Laboratories Clients

We are excited to announce that CSI has been rebranded as Fulgent Oncology.
If you have any questions, please contact your account manager.

Lumera™ HRR-HRD Molecular Profile

Genomic Instability Testing for Solid Tumor
Access TRF
Nurse is comforting a patient.
TEST DESCRIPTION
The Lumera HRR-HRD Molecular Profile is a specialized NGS-based test that identifies diagnostic biomarkers relating to expected PARP inhibitor response, as well as other DNA-damaging agents that exploit HRD vulnerabilities. This test analyzes levels of genomic instability and the presence of oncogenic variants in 15 homologous recombination repair (HRR) genes to determine the homologous recombination deficiency (HRD) score of the solid tumor specimen tested.
  • HRR Method: NGS
  • HRD Method: NGS
  • HRR Coverage: >97% SNV detection, average 500x coverage
  • Turnaround Time: 10 business days from receipt of specimen in the laboratory
SPECIMEN REQUIREMENTS
1 FFPE Tumor Block or a minimum of 10 unstained slides

SHIPPING
Contact us to request a kit
info@fulgentoncology.com
A nurse is happily counseling a patient.

Improved Therapy Recommendations

This test is ideal for patients with solid tumors who want to receive additional information on their tumor sample. It can be particularly useful for patients with ovarian, peritoneal, fallopian tube, or prostate cancer to determine possible qualification for PARP inhibitors (PARPi) and adjuvant chemotherapeutics like platinum and taxanes.
This HRR/HRD test will report oncogenic changes in 15 HRR genes. It will report HRD score (high/low) by assessing the extent of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large scale transitions (LST) copy number alterations. It will list appropriate FDA recommended therapies.
*This test can be ordered as a standalone test or as part of the Lumera Xpanded Solid Tumor Profile
Evaluates 15 HRR genes for SNVs and indels
Reports HRD status high/low, the decision threshold and the HRD score
VAF ≥2.5% are reported

How It Works

For HRR-HRD Testing
Place an order
Order on the portal or download and fill out our paper requisition.
Fulgent will procure the block
Our logistics team will initiate collection immediately upon order receipt and keep your team informed throughout.
Receive your report
All reports will be available for download in your portal within 10 business days.

Gene List

ATMCDK12PPP2R2A
BARD1CHEK1RAD51B
BRCA1CHEK2RAD51C
BRCA2FANCLRAD51D
BRIP1PALB2RAD54L

Additional Resources

  • References
    PMID: 35274707
  • Download Flyer
    Lumera™ HRR-HRD Molecular Profile Flyer
A woman smiling in a call with headphones.

Ready to learn more?

Connect with our experts to learn more about how we can help.
Get in Touch
Follow Us
Products
Lumera Xpanded Solid Tumor Profile Lumera NGS Profile for Solid TumorsLumera Comprehensive Hematological EvaluationLumera Heme NGS ProfileLumera Liquid BiopsyLumera HRR-HRD Molecular ProfileHereditary Cancer Testing
Resources
Forms & RequisitionsBillingQuality & AccreditationOnline Portals
Company
AboutMedical TeamInvestorsContact Us

Website Terms of Use
Privacy Policy
Cookie Policy
HIPAA Notice of Privacy Practices
2025 Ⓒ Fulgent Oncology.
All rights reserved.